Skip to main content

NEW YORK (TheStreet) -- Shares of cancer immunotherapy developer Advaxis  (ADXS) - Get Advaxis, Inc. Report soared more than 15% to hit a new 52-week high of $9.75 on Monday on higher-than-average volume.

More than 2.1 million shares of the stock had changed hands by 12:23 p.m., compared to the daily average volume of 285,730. The stock rose alongside fellow immunotherapy developer Juno Therapeutics  (JUNO) , which soared to new highs on Monday just days after its IPO.

The FDA cleared Advaxis' Investigational New Drug application to begin a Phase 1/2 trial of ADXS-HPV to treat HPV-associated cervical cancer and HPV-associated head and neck cancer. Advaxis expects to begin patient enrollment in the trial in early 2015.

Exclusive Report:Jim Cramer’s Best Stocks for 2015

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Recommends

Image placeholder title

ADXS

data by

YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.